• +1-646-491-9876
    • +91-20-67278686

    Search

    Bullous Pemphigoid-Pipeline Review H1 2017

    Bullous Pemphigoid-Pipeline Review H1 2017

    • Report Code ID: RW0001834371
    • Category Pharmaceuticals
    • No. of Pages 51
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Bullous Pemphigoid - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid - Pipeline Review, H1 2017, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.

    Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. If untreated, it can persist for months or years, with periods of spontaneous remissions and exacerbations. The disease can be fatal, particularly in patients who are debilitated.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2 and 1 respectively.

    Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology) .
    - The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Bullous Pemphigoid - Overview
    Bullous Pemphigoid - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Bullous Pemphigoid - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Bullous Pemphigoid - Companies Involved in Therapeutics Development
    Akari Therapeutics Plc
    Eli Lilly and Company
    iCo Therapeutics Inc.
    Immungenetics AG
    TxCell SA
    Bullous Pemphigoid - Drug Profiles
    bertilimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Coversin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dimethyl fumarate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ENTX-BP - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ixekizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TNT-009 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bullous Pemphigoid - Dormant Projects
    Bullous Pemphigoid - Product Development Milestones
    Featured News & Press Releases
    Feb 28, 2017: Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid
    Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States
    Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid
    Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid
    Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine
    Jun 25, 2015: Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid
    Mar 31, 2015: Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab
    Feb 05, 2015: Immune Pharmaceuticals To Present At The BIO CEO & Investor Conference
    Dec 09, 2014: CEO Dr. Daniel Teper of Immune Pharmaceuticals to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014
    Jul 30, 2014: Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Bullous Pemphigoid, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Bullous Pemphigoid - Pipeline by Akari Therapeutics Plc, H1 2017
    Bullous Pemphigoid - Pipeline by Eli Lilly and Company, H1 2017
    Bullous Pemphigoid - Pipeline by iCo Therapeutics Inc., H1 2017
    Bullous Pemphigoid - Pipeline by Immungenetics AG, H1 2017
    Bullous Pemphigoid - Pipeline by TxCell SA, H1 2017
    Bullous Pemphigoid - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Bullous Pemphigoid, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Akari Therapeutics Plc
    Eli Lilly and Company
    iCo Therapeutics Inc.
    Immungenetics AG
    TxCell SA

    Request for Sample

    Report Url https://www.reportsweb.com//bullous-pemphigoid-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//bullous-pemphigoid-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//bullous-pemphigoid-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments